Chronic allograft nephropathy.
Chronic allograft nephropathy (CAN) remains the Achilles heel of renal transplantation. In spite of the significant strides achieved in one-year renal allograft survival with newer immunosuppressant strategies, the fate of long-term renal allograft survival remains unchanged. The number of renal transplant recipients returning to dialysis has doubled in the past decade. This is especially important since these patients pose a significantly increased likelihood of dying while on the waiting list for retransplantation, due to increasing disparity between donor organ availability versus demand and longer waiting time secondary to heightened immunologic sensitization from their prior transplants. In this review we analyze the latest literature in detail and discuss the definition, natural history, pathophysiology, alloantigen dependent and independent factors that play a crucial role in CAN and the potential newer therapeutic targets on the horizon. This article highlights the importance of early identification and careful management of all the potential contributing factors with particular emphasis on prevention rather than cure of CAN as the core management strategy.
Vadivel
Nidyanandh
N
Transplantation Research Center, Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. nvadivel@rics.bwh.harvard.edu
Tullius
Stefan G
SG
Chandraker
Anil
A
D014943:Global Health; D006084:Graft Rejection / Q000150:complications* / Q000453:epidemiology / Q000473:pathology; D006085:Graft Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D016030:Kidney Transplantation; D015995:Prevalence; D014184:Transplantation, Homologous